Tricia E. Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tricia E. Wright has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Abby C. Collier
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada
1 shared publication Andreea A. Creanga
Department of International Health and International Center for Maternal and Newborn Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
1 shared publicationCheryl Boyce
Division of Clinical Neuroscience and Behavioral Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD
1 shared publicationCorrie B. Miller
1 shared publicationElizabeth Tam
1 shared publicationEric Fombonne
1 shared publication
Latest Publications
- 19 December 2018
- Published by SAGE Publications in Academic Forensic Pathology
- Vol. 8 (4) , 865-873
Investigating Mechanisms of Stillbirth in the Setting of Prenatal Substance Use
Intrauterine fetal demise affects between 0.4-0.8% of pregnancies worldwide. This significant adverse pregnancy outcome continues to be poorly understood. In utero exposure to substances increases the risk of stillbirth to varying degrees according to the type of substance and degree of exposure. The aim of this qualitative narrative review is to investigate common biologic relationships between stillbirth and maternal substance use. A PubMed literature search was conducted to query the most commonly used substances and biologic mechanisms of stillbirth. Search terms included “stillbirth,” “intrauterine fetal demise,” “placenta,” “cocaine,” “tobacco,” “alcohol,” “methamphetamines,” “opioids/ opiates,” and “cannabis.” There are very few studies identifying a direct link between substance use and stillbirth. Several studies demonstrate associations with placental lesions of insufficiency including poor invasion, vasoconstriction, and sequestration of toxic substances that inhibit nutrient transport. Restricted fetal growth is the most common finding in pregnancies complicated by all types of substance use. More research is needed to understand the biologic mechanisms of stillbirth. Such knowledge will be foundational to understanding how to prevent and treat the adverse effects of substances during pregnancy.
- 19 December 2018
- Published by SAGE Publications in Academic Forensic Pathology
- Vol. 8 (4) , 865-873
Investigating Mechanisms of Stillbirth in the Setting of Prenatal Substance Use
Intrauterine fetal demise affects between 0.4-0.8% of pregnancies worldwide. This significant adverse pregnancy outcome continues to be poorly understood. In utero exposure to substances increases the risk of stillbirth to varying degrees according to the type of substance and degree of exposure. The aim of this qualitative narrative review is to investigate common biologic relationships between stillbirth and maternal substance use. A PubMed literature search was conducted to query the most commonly used substances and biologic mechanisms of stillbirth. Search terms included “stillbirth,” “intrauterine fetal demise,” “placenta,” “cocaine,” “tobacco,” “alcohol,” “methamphetamines,” “opioids/ opiates,” and “cannabis.” There are very few studies identifying a direct link between substance use and stillbirth. Several studies demonstrate associations with placental lesions of insufficiency including poor invasion, vasoconstriction, and sequestration of toxic substances that inhibit nutrient transport. Restricted fetal growth is the most common finding in pregnancies complicated by all types of substance use. More research is needed to understand the biologic mechanisms of stillbirth. Such knowledge will be foundational to understanding how to prevent and treat the adverse effects of substances during pregnancy.
- 1 August 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (2) , 214-221
Screening, brief intervention, and referral to treatment for opioid and other substance use during infertility treatment
- 1 August 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (2) , 214-221
Screening, brief intervention, and referral to treatment for opioid and other substance use during infertility treatment
- 1 November 2016
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 215 (5) , 539-547
The role of screening, brief intervention, and referral to treatment in the perinatal period
- 1 November 2016
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 215 (5) , 539-547
The role of screening, brief intervention, and referral to treatment in the perinatal period
- 27 October 2015
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 9 (2) , 65-71
Biochemical Screening for in utero Drug Exposure
Licit and illicit drug use is a common complication of pregnancy. Accurate information on drug use is difficult to obtain for many reasons as women fear self-disclosure or consenting for drug testing due to stigma, guilt, and fear of social and legal harm. As information about drug use is clinically very important, biochemical testing is an important adjunct to careful maternal history. In addition, research studies depend on accurate measures of exposure when reporting risks of a substance. This paper delineates available matrices for and methods of biochemical drug testing in pregnant women and neonates.
- 27 October 2015
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 9 (2) , 65-71
Biochemical Screening for in utero Drug Exposure
Licit and illicit drug use is a common complication of pregnancy. Accurate information on drug use is difficult to obtain for many reasons as women fear self-disclosure or consenting for drug testing due to stigma, guilt, and fear of social and legal harm. As information about drug use is clinically very important, biochemical testing is an important adjunct to careful maternal history. In addition, research studies depend on accurate measures of exposure when reporting risks of a substance. This paper delineates available matrices for and methods of biochemical drug testing in pregnant women and neonates.
- 1 March 2015
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 9 (2) , 111-117
Methamphetamines and Pregnancy Outcomes
Introduction: Methamphetamine (MA) is one of the most commonly used illicit drugs in pregnancy, yet studies on MA-exposed pregnancy outcomes have been limited because of retrospective measures of drug use; lack of control for confounding factors; other drug use, including tobacco; poverty; poor diet; and lack of prenatal care. This study presents prospective collected data on MA use and birth outcomes, controlling for most confounders. Materials and Methods: This is a retrospective cohort study of women obtaining prenatal care from a clinic treating women with substance use disorders, on whom there are prospectively obtained data on MA and other drug use, including tobacco. Methamphetamine-exposed pregnancies were compared with non-MA exposed pregnancies and non–drug-exposed pregnancies, using univariate and multivariate analysis to control for confounders. Results: One hundred forty-four infants were exposed to MA during pregnancy, 50 had first trimester exposure only, 45 had continuous use until the second trimester, 29 had continuous use until the third trimester, but were negative at delivery, and 20 had positive toxicology at delivery. There were 107 non–MA-exposed infants and 59 infants with no drug exposure. Mean birth weights were the same for MA-exposed and nonexposed infants (3159 g vs 3168 g; P = 0.9), although smaller than those without any drug exposure (3159 vs 3321; P = 0.04), infants with positive toxicology at birth (meconium or urine) were smaller than infants with first trimester exposure only (2932 g vs 3300 g; P = 0.01). Gestation was significantly shorter among the MA-exposed infants than that among nonexposed infants (38.5 vs 39.1 weeks; P = 0.045), and those with no drug exposure (38.5 vs 39.5; P = 0.0011), the infants with positive toxicology at birth had a clinically relevant shortening of gestation (37.3 weeks vs 39.1; P = 0.0002). Conclusions: Methamphetamine use during pregnancy is associated with shorter gestational ages and lower birth weight, especially if used continuously during pregnancy. Stopping MA use at any time during pregnancy improves birth outcomes, thus resources should be directed toward providing treatment and prenatal care.
- 1 March 2015
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 9 (2) , 111-117
Methamphetamines and Pregnancy Outcomes
Introduction: Methamphetamine (MA) is one of the most commonly used illicit drugs in pregnancy, yet studies on MA-exposed pregnancy outcomes have been limited because of retrospective measures of drug use; lack of control for confounding factors; other drug use, including tobacco; poverty; poor diet; and lack of prenatal care. This study presents prospective collected data on MA use and birth outcomes, controlling for most confounders. Materials and Methods: This is a retrospective cohort study of women obtaining prenatal care from a clinic treating women with substance use disorders, on whom there are prospectively obtained data on MA and other drug use, including tobacco. Methamphetamine-exposed pregnancies were compared with non-MA exposed pregnancies and non–drug-exposed pregnancies, using univariate and multivariate analysis to control for confounders. Results: One hundred forty-four infants were exposed to MA during pregnancy, 50 had first trimester exposure only, 45 had continuous use until the second trimester, 29 had continuous use until the third trimester, but were negative at delivery, and 20 had positive toxicology at delivery. There were 107 non–MA-exposed infants and 59 infants with no drug exposure. Mean birth weights were the same for MA-exposed and nonexposed infants (3159 g vs 3168 g; P = 0.9), although smaller than those without any drug exposure (3159 vs 3321; P = 0.04), infants with positive toxicology at birth (meconium or urine) were smaller than infants with first trimester exposure only (2932 g vs 3300 g; P = 0.01). Gestation was significantly shorter among the MA-exposed infants than that among nonexposed infants (38.5 vs 39.1 weeks; P = 0.045), and those with no drug exposure (38.5 vs 39.5; P = 0.0011), the infants with positive toxicology at birth had a clinically relevant shortening of gestation (37.3 weeks vs 39.1; P = 0.0002). Conclusions: Methamphetamine use during pregnancy is associated with shorter gestational ages and lower birth weight, especially if used continuously during pregnancy. Stopping MA use at any time during pregnancy improves birth outcomes, thus resources should be directed toward providing treatment and prenatal care.
- Open Access
- 19 January 2012
- Published by Springer Nature in Harm Reduction Journal
- Vol. 9 (1) , 5
Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women
Methamphetamine (MA) use during pregnancy is associated with many pregnancy complications, including preterm birth, small for gestational age, preeclampsia, and abruption. Hawaii has lead the nation in MA use for many years, yet prior to 2007, did not have a comprehensive plan to care for pregnant substance-using women. In 2006, the Hawaii State Legislature funded a pilot perinatal addiction clinic. The Perinatal Addiction Treatment Clinic of Hawaii was built on a harm-reduction model, encompassing perinatal care, transportation, child-care, social services, family planning, motivational incentives, and addiction medicine. We present the implementation model and results from our first one hundred three infants (103) seen over 3 years of operation of the program.
- 19 January 2012
- Published by Springer Nature in Harm Reduction Journal
- Vol. 9 (1) , 5
Open AccessImplementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women
Methamphetamine (MA) use during pregnancy is associated with many pregnancy complications, including preterm birth, small for gestational age, preeclampsia, and abruption. Hawaii has lead the nation in MA use for many years, yet prior to 2007, did not have a comprehensive plan to care for pregnant substance-using women. In 2006, the Hawaii State Legislature funded a pilot perinatal addiction clinic. The Perinatal Addiction Treatment Clinic of Hawaii was built on a harm-reduction model, encompassing perinatal care, transportation, child-care, social services, family planning, motivational incentives, and addiction medicine. We present the implementation model and results from our first one hundred three infants (103) seen over 3 years of operation of the program.
- Open Access
- 9 December 2010
- Published by Springer Nature in Journal of Perinatology
- Vol. 31 (5) , 324-329
Agreement of umbilical cord drug and cotinine levels with maternal self-report of drug use and smoking during pregnancy
Objective: We undertook this study to assess the agreement between fetal umbilical cord drug levels and maternal self-report. Study Design: Cord samples were collected from 103 placentas after delivery as a subproject of the larger Pacific Research Center for Early Human Development (PRCEHD) study. These cord samples were then processed to obtain cord lysates and enzyme-linked immunosorbent assay (ELISA) performed for cotinine and illicit drugs. Levels of each of these substances were compared with clinical information. Result: We found fair agreement between self-reported smoking and cotinine levels (κ=0.26 (0.07 to 0.5)) as well as slight agreement with current drug use and positive drug levels (κ=0.19 (−0.05 to 0.4)). Compared with maternal self-report, sensitivity of cotinine levels was 27% and specificity was 98%. Sensitivity of positive cord illicit drug levels was 32% and specificity was 85%. Conclusion: Umbilical cords provide another independent measure of maternal drug use and are readily available. To our knowledge, this is the first study to measure cotinine levels in the umbilical cord tissue.
- 9 December 2010
- Published by Springer Nature in Journal of Perinatology
- Vol. 31 (5) , 324-329
Open AccessAgreement of umbilical cord drug and cotinine levels with maternal self-report of drug use and smoking during pregnancy
Objective: We undertook this study to assess the agreement between fetal umbilical cord drug levels and maternal self-report. Study Design: Cord samples were collected from 103 placentas after delivery as a subproject of the larger Pacific Research Center for Early Human Development (PRCEHD) study. These cord samples were then processed to obtain cord lysates and enzyme-linked immunosorbent assay (ELISA) performed for cotinine and illicit drugs. Levels of each of these substances were compared with clinical information. Result: We found fair agreement between self-reported smoking and cotinine levels (κ=0.26 (0.07 to 0.5)) as well as slight agreement with current drug use and positive drug levels (κ=0.19 (−0.05 to 0.4)). Compared with maternal self-report, sensitivity of cotinine levels was 27% and specificity was 98%. Sensitivity of positive cord illicit drug levels was 32% and specificity was 85%. Conclusion: Umbilical cords provide another independent measure of maternal drug use and are readily available. To our knowledge, this is the first study to measure cotinine levels in the umbilical cord tissue.
- 1 January 2010
- Vol. 20, S1-215
Disparate rates of persistent smoking and drug use during pregnancy of women of Hawaiian ancestry.
Significant disparity in smoking rates has been previously reported in pregnant and non-pregnant women of Native Hawaiian ancestry. Disparities in drug use rates have also been reported in non-pregnant women of Native Hawaiian ancestry. We undertook this study to compare rates of smoking and drug use during pregnancy among women in Hawaii to see if these differences are associated with disparities in pregnancy complications among Native Hawaiian women. Women were enrolled in the Pacific Research Center on Early Human Development study from July 2007 to January 2008, according to approved protocols. Persistent smoking was defined as self-reported smoking within 1 week of admission for labor. Drug use data was assessed by self-report, or if available, toxicology tests at the time of labor. There were 868 women enrolled in the study during this period. Women of Hawaiian/part-Hawaiian ancestry comprised 22% of the study population. Rates of persistent smoking and drug use among Hawaiian women were significantly higher than the remainder of the study population (21% and 8.3% vs. 7.8% and 2.1%, respectively, P < .001 for both). Methamphetamine use was associated with an almost 5-fold increase in preterm birth and smoking a 3.4% decrease in birth weights. Women of Hawaiian ancestry continue to smoke and use illicit drugs during pregnancy at significantly higher rates than women of other ethnic groups in Hawaii. In addition to the immediate effects on pregnancy, long-term adverse outcomes of in utero exposures of the offspring remain an important health disparity.
- 1 January 2010
- Vol. 20, S1-215
Disparate rates of persistent smoking and drug use during pregnancy of women of Hawaiian ancestry.
Significant disparity in smoking rates has been previously reported in pregnant and non-pregnant women of Native Hawaiian ancestry. Disparities in drug use rates have also been reported in non-pregnant women of Native Hawaiian ancestry. We undertook this study to compare rates of smoking and drug use during pregnancy among women in Hawaii to see if these differences are associated with disparities in pregnancy complications among Native Hawaiian women. Women were enrolled in the Pacific Research Center on Early Human Development study from July 2007 to January 2008, according to approved protocols. Persistent smoking was defined as self-reported smoking within 1 week of admission for labor. Drug use data was assessed by self-report, or if available, toxicology tests at the time of labor. There were 868 women enrolled in the study during this period. Women of Hawaiian/part-Hawaiian ancestry comprised 22% of the study population. Rates of persistent smoking and drug use among Hawaiian women were significantly higher than the remainder of the study population (21% and 8.3% vs. 7.8% and 2.1%, respectively, P < .001 for both). Methamphetamine use was associated with an almost 5-fold increase in preterm birth and smoking a 3.4% decrease in birth weights. Women of Hawaiian ancestry continue to smoke and use illicit drugs during pregnancy at significantly higher rates than women of other ethnic groups in Hawaii. In addition to the immediate effects on pregnancy, long-term adverse outcomes of in utero exposures of the offspring remain an important health disparity.